Nebraska Awarded $9 Million Grant for Lymphoma Research
The University of Nebraska Medical Center has received a nearly $9 million grant from the NCI for research aimed at improving the diagnosis of lymphomas. Researchers are using microarrays, or gene chips, to study cancerous genes. They hope to learn more about lymphoma, find better ways to diagnose it and predict patient outcomes and eventually find targets for new therapies.
The work also involves researchers at the cancer institute and in New York, Arizona, Ohio, Canada, Spain, the United Kingdom, Germany and Norway. Ultimately, the researchers hope to increase patients' chances of survival.
The technology helps researchers profile or decode genes to find out what is causing the cancer. The team so far has discovered so- called signatures that appear to define different types of lymphomas. Omaha World-Herald
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
